4010-81-5

Basic information

• Product Name: 2-chloro-6-(morpholin-4-yl)-5H-purine
• CAS NO: 4010-81-5
• Molecular Formula: C₉H₁₀ClN₅O
• Molecular Weight: 239.6616
• Mol File: 4010-81-5.mol
• Article Data: 26

Chemical Properties

• Boiling Point: 373.3°C at 760 mmHg
• Flash Point: 179.6°C
• Density: 1.74g/cm³
• Vapor Pressure: 9.06E-06mmHg at 25°C
• Refractive Index: 1.796
• CAS DataBase Reference: 2-chloro-6-(morpholin-4-yl)-5H-purine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chloro-6-(morpholin-4-yl)-5H-purine(4010-81-5)
• EPA Substance Registry System: 2-chloro-6-(morpholin-4-yl)-5H-purine(4010-81-5)

Safety Data

• Hazardous Substances Data: 4010-81-5(Hazardous Substances Data)

Usage

Description

2-chloro-6-(morpholin-4-yl)-5H-purine, also known as compound CMPD000065278, is a synthetic purine derivative featuring a purine core with a morpholine group and a chlorine atom attached at specific positions. This chemical compound holds promise for pharmaceutical applications, particularly as a kinase inhibitor, and serves as a chemical building block in the synthesis of other molecules. Its unique structure positions it as a candidate for further research and development in medicinal chemistry.

Uses

Used in Pharmaceutical Industry:
2-chloro-6-(morpholin-4-yl)-5H-purine is used as a kinase inhibitor for its potential role in the development of targeted therapies against various diseases, including cancer. Its ability to inhibit specific kinases may contribute to the regulation of cellular processes and the suppression of disease progression.
Used in Medicinal Chemistry Research:
As a chemical building block, 2-chloro-6-(morpholin-4-yl)-5H-purine is utilized in the synthesis of other molecules with potential therapeutic applications. Its structural features make it a valuable component in the design and development of novel compounds with improved pharmacological properties.
Used in Drug Discovery:
2-chloro-6-(morpholin-4-yl)-5H-purine serves as a starting point for drug discovery efforts, where its modification and optimization can lead to the creation of new drugs with enhanced efficacy and selectivity. Its potential as a kinase inhibitor highlights its importance in the search for treatments for various diseases.

Upstream product

• 110-91-8 morpholine 
• 5451-40-1 2,6-dichloropurine 
• 5451-40-1 2,6 dichloropurine 
• 10310-21-1 2-Amino-6-chloropurin 
• 73-40-5 2-amino-1,9-dihydro-6H-purin-6-one 
• 149948-30-1 N-(6-chloro-9H-purin-2-yl)formamide 
• 5451-40-1 2,6-dichloro-7H-purine 
• 95758-04-6 2-chloro-6-(morpholin-4-yl)-9-(tetrahydro-2H-pyran-2-yl)-9H-purine 

Downstream Products

• 7474-73-9 6-morpholino-2-piperidino-7(9)H-purine 
• 2846-96-0 6-morpholino-7⁽⁹⁾H-purine 
• 7471-61-6 (6-morpholino-7(9)H-purin-2-yl)-hydrazine 
• 7494-71-5 4,4'-(9H-purine-2,6-diyl)dimorpholine 
• 1062203-86-4 [4-(6-morpholin-4-yl-9H-purin-2-yl)phenyl]methanol 
• 1062203-80-8 2-(6-morpholin-4-yl-9H-purin-2-yl)phenol 
• 1062203-83-1 4-(6-morpholin-4-yl-9H-purin-2-yl)phenol 
• 1062204-03-8 3-(6-morpholin-4-yl-9H-purin-2-yl)benzonitrile 
• 1062204-08-3 N-(3-(6-morpholino-9H-purin-2-yl)phenyl)methanesulfonamide 
• 1062204-17-4 2-[3-(methylsulfonyl)phenyl]-6-morpholin-4-yl-9H-purine 
• 1062204-20-9 2-(4-Methanesulfonyl-phenyl)-6-morpholin-4-yl-9H-purine 
• 1208243-80-4 C₁₆H₁₆N₆O₂ 
• 1148003-35-3 4-(2-chloro-9-methyl-9H-purin-6-yl)morpholine 
• 1392421-29-2 3-[2-((2S,6R)-2,6-dimethyl-morpholin-4-yl)-6-morpholin-4-yl-9H-purin-8-yl]-phenol 

Relevant articles and documents

High yielding, base catalyzed C6 regioselective amination and N9 alkylation in purine nucleotide

2,6-Dichloropurine is an interesting new nucleoside which gave regioselectively various 2-derivatized or 6-derivatized purines by using a secondary amines. An efficient, simple and regioselective synthesis of C6 morpholine, N9 alkylated purine nucleoside derivatives were attained via chloro-amine coupling reaction between 2,6-dichloropurine with morpholine followed by commercial alkylation method using DMF and K2CO3. Over the traditionally used protocols and procedure, it have been exhibited advance benefits such as admirable yield, simple reaction conditions and modest influence.

Piperazinone substitute or derivative thereof, preparation method and application thereof, and pharmaceutical composition

The invention relates to a piperazinone substitute or a derivative thereof, a preparation method and application thereof, and a pharmaceutical composition, and belongs to the technical field of anti-tumor drugs. The invention designs a piperazinone substituted heterocyclic small molecule compound. The compound shows good affinity to PI3K delta, and the compound can down-regulate the activity of a PI3K pathway in tumor cells, so that the compound shows good inhibitory activity to PI3K delta dependent tumors, and is expected to be used as one of components of a pharmaceutical preparation for treatment of different tumors. The preparation method of the piperazinone substitute is simple and convenient, and the yield is relatively high.

DUAL KINASE-BROMODOMAIN INHIBITORS

Provided herein are compounds of Formula (I) that are dual inhibitors of kinases and bromo-domain proteins. The disclosure also relates to pharmaceutical compositions containing such compounds, methods for using such compounds in the treatment of cancers, particularly, the treatment of multiple myeloma cancers, and to related uses.

Purine compound obtained based on virtual docking as well as preparation method and application of same

The invention provides a purine compound obtained based on virtual docking. The purine compound is screened in a virtual screening and pharmacophore manner, through a result of mutual evidence verification of virtual docking design and compound synthesis,